Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2013, Pages 662-669

  Htun, Patrik ^a   Kan, Tatiana ^b   Mueller, Eda ^b   Pohle, Cosima ^c   Schindler, Ralf ^d   Geisler, Tobias ^e   Gawaz, Meinrad ^e   Bocksch, Wolfgang ^e   Fateh Moghadam, Suzanne ^e  

^a KLINIKUM AUGSBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c KfH Kuratorium für Dialyse und Nierentransplantation eV KfH Nierenzentrum Berlin ^*  (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antiplatelet therapy; Aspirin low responder; Clopidogrel low responder; End stage renal disease; Haemodialysis

Indexed keywords

ACETYLSALICYLIC ACID; BICARBONATE; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG RESPONSE; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMPLICATION; DRUG EFFECTS; FOLLOW UP; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PILOT STUDY; RENAL REPLACEMENT THERAPY; RISK; THROMBOCYTE; THROMBOCYTE ACTIVATION;

AGED; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; RENAL DIALYSIS; RISK; TICLOPIDINE;

EID: 84897495991     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0289     Document Type: Article

References (45)

1. Renal Data System: USRDS 2002 Annual Data report. Bethesda. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
2. Renal Data System: USRDS 2000 Annual Data report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2000.
3. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
4. Huber K, Schrör K. High on-treatment platelet reactivity-why should we be concerned? Thromb Haemost 2013; 109: 789-791.
5. Cattaneo M. High on-treatment platelet reactivity-definition and measurement. Thromb Haemost 2013; 109: 792-798.
6. Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
7. Angiolillo DJ, Ferndandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
8. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61.
9. Geisler T, Kapp M, Goehring-Frischholz K, et al. Residual platelet activity is increased in clopidogrel-and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94: 743-747.
10. Fernando H, Dart AM, Peter KH, et al. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 2011; 105: 933-944.
11. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104: 1292-1295.
12. Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study Am Heart J 2011; 162: 1018-1025.
13. Alexopoulos D, Xanthopoulou I, Panagiotou A, et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving haemodiaysis. Am J Kidney Dis 2012: 59: 469-471.
14. Sibbing D, Byrne RA, Bernlocher I, et al. High platelet reactivity and clinical outcome-fact and fiction. Thromb Haemost 2011; 106: 191-202.
15. Latif F, Kleiman NS, Cohen DJ, et al. EVENT Investigator (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009; 2: 37-45.
16. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients. J Am Coll Cardiol 2007; 50: 501-508.
17. Iakovou I, Schmidt T, Bonizzoni E Ge L, et al. Incidence, predictors and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-2130.
18. Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol 2011; 22: 627-633.
19. Alexopoulos D, Xanthopoulou I, Plakomyti TE, et al. Ticagrelor in clopidogrelresistant patients undergoing maintenance dialysis. Am J Kidney Dis 2012; 60: 332-333.
20. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625-2632.
21. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JACC 2010; 56: 919-933.
22. Valgimigli M, Campo G, de Cesare N, et al. On behalf of Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study. Circulation 2009; 119: 3215-3222.
23. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point of care assay: a 12-month follow up. Circulation 2009; 119: 237-342.
24. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur J Heart 2008; 29: 992-1000.
25. Breet NJ, Van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
26. Geara AS, Ayoub I, Abi Rached J, et al. Does haemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test? Am J Cardiol 2011 107: 1103-1104.
27. Aggarwal A, Kabbani SS, Rimmer JM, et al. Biphasic effects of haemodialysis on platelet reactivity in patients with end-stage renal disease: a potential contributor to cardiovascular risk. Am J Kidney Dis 2002; 40: 315-322.
28. Sirolli V, Strizzi L, Di Stante S, et al. Platelet activation and platelet-erythrocyte aggregates in endstage renal disease patients on haemodialysis. Thromb Haemost 2001; 86: 834-839.
29. Gawaz MP, Mujais SK, Schmidt B et al. Platelet-leukocyte aggregation during haemodialysis. Kidney Int 1994; 46: 489-495.
30. Bonomini M, Sirolli V, Stuard S, et al. Interactions between platelets and leukocytes during haemodialysis. Artif Organs 1999; 23: 23-28.
31. Daugirdas JT, Bernardo AA, et al. Haemodialysis effect on platelet count and function and haemodialysis-associated thrombocytopenia. Kidney Int 2012; 16: 147-157.
32. Himmelfarb J, Holbrook D, McMonagle E, Ault K. Increased reticulated platelets in dialysis patients. Kidney Int 1997; 51: 834-839.
33. Linthorst GE, Folman CC, van Olden RW, et al. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002; 3: 38-42.
34. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-2725.
35. Arazi HC, Doiny DG, Torcivia RS, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact Cardiovasc Thorac Surg 2010; 10: 863-867.
36. Grooteman MP, Nube MJ. Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter? Nephrol Dial Transplant 2004; 19: 2965-2970.
37. MacLeod AM, Campbell M, Cody JD, et al. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 2005; CD003234.
38. Schindler R, Boenisch O, Fischer C, et al. Effect of the haemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452-459.
39. Tanrikulu AM, Ozben B, Koc M, et al. Aspirin resistance in patients with chronic renal failure. J Nephrol 2011; 24: 636-646.
40. Tantry US, Bliden KP, Gurbel P, et al. Resistance to antiplatelet drugs. Current status and future research. Expert Opin Pharmacother 2005; 6: 2027-2045.
41. Small DS, Wrishko RE, Ernest CS 2nd, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009; 34: 585-594.
42. Mega JL, Close SL, Wiviott SD, et al Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic and clinical outcomes. Circulation 2009; 119: 2553-2560.
43. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
44. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. A. Antiplatelet effects of Prasugrel vs double clopidogrel in patients on haemodialysis and with high ontreatment platelet reactivity. J Thromb Haemost 2011; 9: 2379-2385.
45. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function Results from the platelet inhibition and patient outcomes (PLATO) Trial. Circulation 2010; 122: 1056-1067.